title: Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
authors.forename: Duncan
authors.initials: D
authors.lastname: Webster
authors.forename: Sivakumaran
authors.initials: S
authors.lastname: Devarajan
authors.forename: Janet
authors.initials: J
authors.lastname: Gallant
authors.forename: Andrew
authors.initials: A
authors.lastname: Harris
authors.forename: Lili C
authors.initials: LC
authors.lastname: Kopala
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine